Toxoplasma gondii Antigen Production Service

Various T. gondii Antigen Structures

The acquisition of Toxoplasma infection may be avoided by developing vaccines based on defined T. gondii antigens. T. gondii contains a variety of various antigenic structures, for example, surface antigen (SAG), microneme antigen (MIC), rhoptry neck (RON) and rhoptry antigen (ROP), and dense granule antigen (GRA). Most vaccines against Toxoplasma are developed based on protein antigens, but resistance may develop. Therefore, some researchers have recently focused on another type of immunogenic molecule, namely the glycosylphosphatidylinositol (GPI) anchor contained in the Toxoplasma cell membrane. GPIs containing additional α-GIc in the side chain are free glycolipids on the plasma membrane, and also known as low molecular weight antigens of T. gondii , trigger human-specific IgM immune responses. Therefore, the GPIs of T. gondii may be applied in vaccine development.

• T. gondii Antigen Production Service at CD BioGlyco
  CD BioGlyco offers different ways of producing T. gondii antigens.
  • CD BioGlyco cultivates and proliferates T. gondii protoplasts, and then extracts proteins with glycosylation modifications. The sugar chains attached to these proteins serve as carbohydrate antigens. It involves steps such as parasite culture and enrichment, cell disruption, antigen extraction, and purification.
  • CD BioGlyco also directly synthesizes the carbohydrate structure related to T. gondii through chemical synthesis and connects it to the carrier to generate a complex with carbohydrate antigenic properties.
• T. gondii Antigen Analysis and Identification Service at CD BioGlyco
  CD BioGlyco performs characterization and activity identification of the prepared antigens, which helps detect the purity, stability, and functional activity of the antigens.
• T. gondii Antigen-based Vaccine Development Service at CD BioGlyco
  CD BioGlyco provides the synthesis of defined compounds derived from T. gondii GPIs. The resulting products are suitable for tests for toxoplasmosis. We have established an excellent Glyco™ Vaccine Development Platform to covalently link the produced T. antigens with appropriate carriers to develop vaccines to combat diseases caused by Toxoplasma infection.

Fig.1 T. gondii antigen production, analysis, and identification services. (CD BioGlyco)

Applications

• Diagnostic reagent research: Preparation of T. gondii antigens is applied to develop diagnostic reagents, which are applied in detecting T. gondii infections.
• Drug screening: Preparation of T. gondii antigens is applied to conduct drug screening and evaluate the activity of candidate antiparasitic compounds, which helps in the discovery of novel drug treatments for T. gondii infections.
• Vaccine research: By preparing T. gondii antigens, their potential to induce immune protection and prevent infection is assessed, which helps develop effective vaccines to prevent T. gondii infections.

Advantages

• CD BioGlyco has a professional technical team with an in-depth understanding of T. gondii and its antigen production. We provide mature and efficient T. gondii antigen production.
• CD BioGlyco has flexible production capacity and scale to meet the needs of small-batch to large-scale production of T. gondii antigen.
• CD BioGlyco ensures the production of high-quality T. gondii antigens, and the products undergo strict quality control and verification.

CD BioGlyco is an excellent biological company with many years of experience in the field of vaccine development and provides the T. gondii antigen production service. Please feel free to contact us if you would like to inquire about specific T. gondii antigen production details.

References

1. Holec-Gąsior, L. Toxoplasma gondii recombinant antigens as tools for serodiagnosis of human toxoplasmosis: current status of studies. Clinical and Vaccine Immunology . 2013, 20(9): 1343-1351.
2. Ferra, B.; et al . Toxoplasma gondii recombinant antigens in the serodiagnosis of toxoplasmosis in domestic and farm animals. Animals . 2020, 10(8): 1245.